Latest Earnings Results: Q2 '26
Estimated EPS
-$0.15
Reported EPS
-$0.09
Surprise
+39.78%
Estimated Rev
$55.34M
Reported Rev
$56.01M
Surprise
+1.21%
• Reported GAAP EPS of -$0.09 up 35.71% YoY • Reported revenue of $56.01M up 15.18% YoY • SI-BONE increases 2026 worldwide revenue guidance to a range of $231 million to $233 million, representing ~15% to 16% growth, while maintaining gross margin at ~79% and updating operating expenses to ~12%.
Bullish Takeaway
SI-BONE delivered double-digit revenue growth and significant improvements in adjusted EBITDA, supported by a growing U.S. physician base and the upcoming launch of a new third-breakthrough device in 2026.
Bearish Takeaway
SI-BONE experienced a slight compression in gross margin, an increase in operating expenses, and faces structural risks related to potential economic weakness and international trade tensions impacting elective procedure demand.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.13 | -- | -- | N/A |
Q2 '26 | -$0.15 | -$0.09 | 39.78% | BEAT |
Q1 '26 | -$0.19 | -$0.10 | 46.69% | BEAT |
Q4 '25 | -$0.13 | -$0.04 | 68.25% | BEAT |
Q3 '25 | -$0.17 | -$0.11 | 33.91% | BEAT |